𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients

✍ Scribed by Frank Lyko; Dirk Stach; Axel Brenner; Stephan Stilgenbauer; Hartmut Döhner; Michaela Wirtz; Manfred Wiessler; Oliver J. Schmitz

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
92 KB
Volume
25
Category
Article
ISSN
0173-0835

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aberrant DNA methylation in pediatric pa
Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia
✍ Guillermo Garcia-Manero; Sima Jeha; Jerry Daniel; Jason Williamson; Maher Albita 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Abstract ## BACKGROUND Aberrant methylation of promoter‐associated cystosine‐guanine (CpG) islands is an epigenetic modification of DNA frequently observed in adult patients with acute lymphocytic leukemia (ALL). This epigenetic modification has been associated with gene silencing, malignant tr

Impaired synthesis of immunoglobulin in
Impaired synthesis of immunoglobulin in patients with chronic lymphocytic leukemia
✍ Anthony S. Kurec; Frederick R. Davey 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 808 KB

The cause of hypogammaglobulinemia in patients with chronic lymphocytic leukemia (CLL) is unknown. Experiments were performed to determine if sera, monocytes, or non-T cells from patients with CLL suppress the proliferative response and synthesis of immunoglobulin (Ig) following incubation with poke

The clinical course of lung carcinoma in
The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia
✍ Kalpaj Parekh; Valerie Rusch; Mark Kris 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

## BACKGROUND. Although patients with chronic lymphocytic leukemia (CLL) have an increased risk of developing second primary malignancies, including lung carcinoma, there is virtually no information about their clinical outcomes. To evaluate this, the authors reviewed their 20-year institutional e

Prognostic value of plasma interleukin-6
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia
✍ Raymond Lai; Susan O'Brien; Taghi Maushouri; Anna Rogers; Hagop Kantarjian; Mich 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Background: Interleukin 6 (il-6) is a b-cell growth and differentiation factor, which may promote the growth of b-cell neoplasms. in chronic lymphocytic leukemia (cll) patients, il-6 plasma levels increased in a stage-dependent manner, suggesting that il-6 may be a useful prognostic marker. the